Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2020 Earnings Results

Madrigal Pharmaceuticals Misses on EPS — Stock Down 4.59%

Madrigal Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a 4.59% decline in its stock price following the earnings announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. The focus on clinical trials suggests that the company is prioritizing long-term growth over short-term financial metrics.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-3.75	N/A	-11.84%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the challenges faced during the quarter. They emphasized a commitment to advancing their clinical programs.

Management did not provide specific guidance for future quarters.

The company is focused on ongoing clinical trials and research.

Madrigal Pharmaceuticals Misses on EPS — Stock Down 4.59%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS — Stock Down 4.59%

Key numbers

Management commentary